NEW BRUNSWICK, N.J. — Johnson & Johnson has started testing its COVID-19 vaccine on adolescents, beginning with those ages 16 and 17.
The teens will be added to an ongoing study of the vaccine in adults that began last September, the New Brunswick, New Jersey-based drugmaker said Friday. After initial data from the older teens is reviewed, the trial will expand to add adolescents ages 12 to 15.
J&J says the first teens are being enrolled in the United Kingdom and Spain. Teens in the United States, Canada and the Netherlands will be added, followed by teens in Brazil and Argentina.
The study is testing the safety and efficacy of both one-dose and two-dose regimens of the vaccine, with the two-dose regimens being studied at intervals of one, two and three months after the first shot.
Dr. Mathai Mammen, global head of research and development for the company’s Janssen pharmaceuticals unit, says it also expects to initiate studies in pregnant women and children.
A total of 100 million J&J doses are pledged for the U.S. by late May or June.
- Click here for the latest CDC novel coronavirus resources and links.
- Track the COVID-19 globally using this map tracker here.
- You can view the latest Indiana COVID-19 numbers here.
- Track Ohio's coronavirus numbers here.
- Need to get tested? Click here to find a testing site near you.
- Check out or COVID-19 vaccine resource page here.
- You can catch up on the latest ABC21 coronavirus coverage here.
- Sign up here for the latest local, state and national news regarding COVID-19.
- Click here to sign up for ABC21 News and Weather Alerts